titoli, abstracts, parole chiave >>>
Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection

Martín-Carbonero, Luz and De Ledinghen, Victor and Moreno, Ana and Maida, Ivana Rita and Foucher, Juliette and Barreiro, Pablo and Romero-Gómez, Manuel and Satta, Giuseppe and Garcia Samaniego, Javier and Gonzalez-Lahoz, Juan and Soriano, Vincent (2009) Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection. Journal of Viral Hepatitis, Vol. 16 (11), p. 790-795. eISSN 1365-2893. Article.

Full text not available from this repository.

DOI: 10.1111/j.1365-2893.2009.01133.x

Abstract

Liver fibrosis progress slowly in patients with chronic hepatitis C and persistently normal alanine aminotransferase (PNALT) compared to subjects with elevated aminotransferases. Differences in liver fibrosis according to human immunodeficiency virus (HIV) status in this population have not been examined. All patients with serum hepatitis C virus (HCV)-RNA and PNALT who underwent liver fibrosis assessment using elastometry since 2004 at three different European hospitals were evaluated. Patients previously treated with interferon were excluded. PNALT was defined as ALT below the upper limit of normality in at least three consecutive determinations within the last 12 months. Fibrosis stage was defined as mild (Metavir F0–F1) if stiffness ≤7.1 kPa; moderate (F2) if 7.2–9.4 kPa; severe (F3) if 9.5–14 kPa, and cirrhosis (F4) if >14 kPa. A total of 449 HIV-negative and 133 HIV-positive patients were evaluated. HIV-negative patients were older (mean age 51.8 vs 43.5 years) and more frequently females (63% vs 37%) than the HIV counterparts. Mean serum HCV-RNA was similar in both the groups (5.9 vs 5.8 log IU/mL). Overall, 78.8% of the HIV patients were on HAART and their mean CD4 count was 525 (±278) cells/μL. In HIV-negatives, liver fibrosis was mild in 84.6%; moderate in 8.7%, severe in 3.3% and cirrhosis was found in 3.3%. In HIV patients, these figures were 70.7%, 18.8%, 6%, and 4.5%, respectively. In the multivariate logistic regression analysis, older age (odds ratio or OR: 1.04; 95% confidence interval or CI: 1.02–1.07; P < 0.001) and being HIV+ (OR: 2.6; 95% CI: 1.21–5.85; P < 0.01) were associated with severe liver fibrosis or cirrhosis (F3–F4). Thus, severe liver fibrosis and cirrhosis are seen in 6.6% of the HCV-monoinfected and in 10.5% of HCV-HIV co-infected patients with PNALT. Some degree of liver fibrosis that justifies treatment is seen in 15% of the HCV-monoinfected but doubles to nearly 30% in HIV-HCV co-infected patients with PNALT.

Item Type:Article
ID Code:3489
Status:Published
Refereed:Yes
Uncontrolled Keywords:Antiretroviral therapy, HCV, HIV, liver enzymes, liver fibrosis
Subjects:Area 06 - Scienze mediche > MED/17 Malattie infettive
Divisions:001 Università di Sassari > 03 Istituti > Malattie infettive e parassitarie
Publisher:Blackwell / Wiley
eISSN:1365-2893
Copyright Holders:© 2010 Blackwell Publishing
Deposited On:26 Jan 2010 11:19

I documenti depositati in UnissResearch sono protetti dalle leggi che regolano il diritto d'autore

Repository Staff Only: item control page